| Case Page

 | Case Page |

Case Page

 

Jaguar Animal Health, Inc.

Case Summary

Jaguar Animal Health, Inc. Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 10/11/2018 (Ongoing date of last review)

Filing Date: July 20, 2017

According to the Complaint, it is alleged Defendants have violated Sections of the Exchange Act by causing a materially incomplete and misleading joint proxy statement/prospectus/information statement (the “Proxy”) to be filed with the SEC and disseminated to Jaguar shareholders. The Proxy recommends that Jaguar shareholders vote in favor of a Proposed Merger whereby Jaguar, in an all-stock transaction, will acquire Napo, with Jaguar continuing as the surviving entity (the “Proposed Merger”).

On December 11, 2017, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on January 10, 2018. Defendants filed a Motion to Dismiss the amended Complaint on March 12. On September 20, the Court issued an Order granting Defendants' Motion to Dismiss. Lead Plaintiff was given leave to amend the Complaint.

Company & Securities Information

Defendant: Jaguar Animal Health, Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: JAGX
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Tony Plant , et al. v. Jaguar Animal Health, Inc., et al.

COURT: N.D. California
DOCKET #: 17-CV-04102
JUDGE: Hon. Richard Seeborg
DATE FILED: 07/20/2017
CLASS PERIOD START: 07/06/2017
CLASS PERIOD END: 07/20/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Monteverde & Associates PC
    350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118
    (212) 971-1341 ·
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint 07/20/2017
2 Notice of Motion of Tony Plant for Appointment as Lead Plaintiff and Approval of Lead Counsel; Memorandum of Law in Support Thereof 10/03/2017
3 U.S. District Court Civil Docket 12/11/2017
4 Order Granting Motion for Appointment of Lead Plaintiff and Lead Counsel 12/11/2017

Reference Complaint

Tony Plant, et al. v. Jaguar Animal Health, Inc., et al.

COURT: N.D. California
DOCKET #: 17-CV-04102
JUDGE: Hon. Richard Seeborg
DATE FILED: 01/10/2018
CLASS PERIOD START: 07/06/2017
CLASS PERIOD END: 07/20/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Monteverde & Associates PC (Culver City)
    600 Corporate Pointe, Suite 1170, Monteverde & Associates PC (Culver City), CA 90230
    310.446.6652 310.446.6652 ·
Reference Complaint (REF) Filings:
No Document Title Filing Date
1 Amended Class Action Complaint 01/10/2018
2 Order Granting Motion to Dismiss 09/20/2018

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases